Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • References
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Corrigendum Free access | 10.1172/JCI135716

Calcium channel Orai1 promotes lymphocyte IL-17 expression and progressive kidney injury

Purvi Mehrotra, Michael Sturek, Javier A. Neyra, and David P. Basile

Find articles by Mehrotra, P. in: JCI | PubMed | Google Scholar

Find articles by Sturek, M. in: JCI | PubMed | Google Scholar

Find articles by Neyra, J. in: JCI | PubMed | Google Scholar

Find articles by Basile, D. in: JCI | PubMed | Google Scholar

Published February 3, 2020 - More info

Published in Volume 130, Issue 2 on February 3, 2020
J Clin Invest. 2020;130(2):1052–1052. https://doi.org/10.1172/JCI135716.
© 2020 American Society for Clinical Investigation
Published February 3, 2020 - Version history
View PDF

Related article:

Calcium channel Orai1 promotes lymphocyte IL-17 expression and progressive kidney injury
Purvi Mehrotra, … , Javier A. Neyra, David P. Basile
Purvi Mehrotra, … , Javier A. Neyra, David P. Basile
Research Article Inflammation Nephrology

Calcium channel Orai1 promotes lymphocyte IL-17 expression and progressive kidney injury

  • Text
  • PDF
Abstract

We hypothesized that the store-operated calcium entry (SOCE) channel, Orai1, participates in the activation of Th17 cells and influences renal injury. In rats, following renal ischemia/reperfusion (I/R), there was a rapid and sustained influx of Orai1+ CD4 T cells and IL-17 expression was restricted to Orai1+ cells. When kidney CD4+ cells of post–acute kidney injury (post-AKI) rats were stimulated with angiotensin II and elevated Na+ (10–7 M/170 mM) in vitro, there was an enhanced response in intracellular Ca2+ and IL-17 expression, which was blocked by SOCE inhibitors 2APB, YM58483/BTP2, or AnCoA4. In vivo, YM58483/BTP2 (1 mg/kg) attenuated IL-17+ cell activation, inflammation, and severity of AKI following either I/R or intramuscular glycerol injection. Rats treated with high-salt diet (5–9 weeks after I/R) manifested progressive disease indicated by enhanced inflammation, fibrosis, and impaired renal function. These responses were significantly attenuated by YM58483/BTP2. In peripheral blood of critically ill patients, Orai1+ cells were significantly elevated by approximately 10-fold and Th17 cells were elevated by approximately 4-fold in AKI versus non-AKI patients. Further, in vitro stimulation of CD4+ cells from AKI patients increased IL-17, which was blocked by SOCE inhibitors. These data suggest that Orai1 SOCE is a potential therapeutic target in AKI and CKD progression.

Authors

Purvi Mehrotra, Michael Sturek, Javier A. Neyra, David P. Basile

×

Original citation: J Clin Invest. 2019;129(11):4951–4961. https://doi.org/10.1172/JCI126108

Citation for this corrigendum: J Clin Invest. 2020;130(2):1052. https://doi.org/10.1172/JCI135716

Following the publication of this article, a reader noted that Figure 4I and Supplemental Figure 1 contained images that were previously published in a Kidney International publication by the same group (1). The authors have indicated that the errors in Figure 4I occurred during figure preparation and have provided the corrected panel below. In addition, the authors have provided an updated version of Supplemental Figure 1 to illustrate the gating strategy used in the study in this article. The online version of the supplemental data has been updated to reflect this change.

The authors regret the error.

Footnotes

See the related article at Calcium channel Orai1 promotes lymphocyte IL-17 expression and progressive kidney injury.

References
  1. Mehrotra P, Patel JB, Ivancic CM, Collett JA, Basile DP. Th-17 cell activation in response to high salt following acute kidney injury is associated with progressive fibrosis and attenuated by AT-1R antagonism. Kidney Int. 2015;88(4):776–784.
    View this article via: PubMed CrossRef Google Scholar
Version history
  • Version 1 (February 3, 2020): Print issue publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts